8-K current report · filed Jul 29, 2026

ACCURAY INC (ARAY) 8-K Current Report: July 29, 2026

Item 1.01Item 5.02Item 8.01Item EX-99.50Item EX-99.50#2Item EX-99.50#3Item EX-99.52Item 3.02Item EX-99.1ARAY overview

Short answer

ACCURAY INC (ARAY) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.50 (Exhibit EX-99.50), Item EX-99.50#2 (Exhibit EX-99.50), Item EX-99.50#3 (Exhibit EX-99.50), Item EX-99.52 (Exhibit EX-99.52), Item 3.02 (Unregistered Sales of Equity Securities), Item EX-99.1 (Item EX-99.1). $55.0M preferred financing: $15.0M cash plus conversion of $40.0M existing debt, contingent on stockholder approval and 1-for-15 to 1-for-40 reverse split.

ACCURAY INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $55.0M preferred financing: $15.0M cash plus conversion of $40.0M existing debt, contingent on stockholder approval and 1-for-15 to 1-for-40 reverse split
  • Series A accrues 8% dividends, carries a $1,000 liquidation preference, and converts initially at approximately $0.50 per share
  • Existing warrants covering approximately 27.6M common shares cancelled, but new seven-year $0.01 warrants cover approximately 15.3M shares
  • TCW gains rights to designate two directors and preferred-holder consent over key financing and governance actions
  • Debt amendment provides covenant relief through December 31, 2027, but adds a $15.0M termination fee and $250,000 amendment fees if approval fails

Item 3.02 · Unregistered Sales of Equity Securities

  • ACCURAY issued Series A Preferred Stock and Warrants in a private placement to accredited investors
  • Transaction exempt from SEC registration under Securities Act Section 4(a)(2)
  • Potential future common-stock issuance upon preferred conversion or warrant exercise, creating dilution risk
  • Transfer restrictions and investment-purpose representations limit near-term resale flexibility

Item 5.02 · Departure/Election of Directors or Officers

  • Beverly Huss and Anne LeGrand resigned from Accuray’s board effective July 29, 2026
  • Departures occurred alongside execution of the Purchase Agreement, indicating transaction-related board turnover
  • No disagreements with Accuray, its board, operations, policies, or practices cited

Item 8.01 · Other Events

  • Purchase Agreement executed, marking a potentially material corporate transaction
  • Press release provides transaction terms and expected strategic or financial impact
  • Investors should review Exhibit 99.1 for purchase price, counterparties, timing, and conditions

Item EX-99.1 · Item EX-99.1

  • Warrant issued to lenders for Financing Agreement Amendment No. 3, signaling lender concessions tied to covenant and liquidity changes
  • Exercise price $0.01 per share, creating potentially substantial dilution if exercised
  • Expiration in 2033, with automatic cashless exercise when market price exceeds exercise price
  • Exercise capped at 4.99%, 9.99%, or 19.9% pending final terms, limiting immediate ownership concentration
  • Anti-dilution protections and resale restrictions enhance holder economics while complicating future equity financing

Item EX-99.50 · Exhibit EX-99.50

  • Warrant issued to financing lenders as consideration for Financing Agreement Amendment No. 3, signaling lender concessions tied to equity upside
  • Exercise price $0.01 per share, creating substantial potential dilution if the warrant’s unspecified shares are exercised
  • Warrant expires in 2033 and permits cash or net-share settlement, with automatic cashless exercise at expiration when in the money
  • Holder ownership and voting limits of 4.99%, 9.99% or 19.9%, subject to final documentation, constrain immediate control impact
  • Financing amendment changes financial covenant and liquidity provisions, making lender support material to Accuray’s near-term financial flexibility

Item EX-99.50#2 · Exhibit EX-99.50

  • $55M recapitalization: $15M new cash plus $40M existing lender debt exchanged for Series A convertible preferred stock
  • Closing depends on stockholder approval and a 1-for-15 to 1-for-40 reverse split targeting at least $8.00 post-split common-stock price
  • New penny warrants exercisable for 15,253,473 common shares, creating substantial potential dilution
  • Existing June 2025 and December 2025 premium and super-premium warrants cancelled at closing
  • Failure to secure approval converts the $15M cash investment into debt and triggers a $15M non-refundable fee payable to lenders

Item EX-99.50#3 · Exhibit EX-99.50

  • Limited waiver addresses defaults from June 30, 2026 liquidity covenant breach and missed July 1 transition requirements
  • $15.0M Term Loan A converted into revolving loans, reducing Term Loan A to $13.4M and setting revolver borrowings at $20.0M
  • Converted debt exchanged for preferred shares, with accrued interest still payable in cash at the next interest payment date
  • Term Loan B lenders receive warrants for 15,253,473 shares at $0.01 per share, creating substantial potential equity dilution
  • $250,000 supplemental premium payable to Revolving and Term Loan A lenders, alongside stricter immediate-default consequences for missed conditions subsequent

Item EX-99.52 · Exhibit EX-99.52

  • TCW debt exchange converts $40M term-loan principal into preferred stock, reducing leverage but introducing preferred dilution risk
  • TCW adds $15M cash investment plus up to $5M delayed-draw liquidity, improving near-term funding flexibility
  • Preferred stock converts at $0.50 per share and accrues 8% dividends, creating potential future dilution and cash or accrued dividend obligations
  • Covenant waivers extend through December 31, 2027, with testing deferred until March 31, 2028, providing execution runway
  • Board reduction from 8 to 7 gives TCW two director appointments, while reverse split and equity issuances require stockholder approval

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ACCURAY INC 8-K filings

Get the next ARAY 8-K as it lands

Follow ARAY for push alerts, or ask the research agent what this filing means.